1. Aiba Y et al. 2015. A highly acid-resistant novel strain of Lactobacillus johnsonii No. 1088 has antibacterial activity, including that against Helicobacter pylori, and inhibits gastrin-mediated acid production in mice. Microbiology 4(3): 465–474.
  1. Alexander LF & Randolph ER. 2011. Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all? World J Gastrointest Pharmacol Ther. 2(3): 17–26.
  1. Gomm W et al. 2016. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol. 73(4): 410-416.
  1. Herzig SJ et al. 2009. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 301(20): 2120-2128.
  1. Ito T & Jensen RT. 2010. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 12(6): 448-457.
  1. Komatsu Y et al. 2016. Probiotics, Prebiotics, and Biogenics for the Stomach. INTECH Chapter 18. 363-381.
  1. Shah NH et al. 2015. Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS One. 10(6): e0124653.
  1. Takahashi H et al. 2011. Role of indigenous lactobacilli in gastrin-mediated acid production in the mouse stomach. Appl Environ Microbiol. 77(19): 6964–6971.
  1. Xie Y et al. 2016. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. J Am Soc Nephrol. 27(10): 3153-3163.